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838FO-5 Immediate Postinfarction Shape Changes Predict the 
Outcome of the Remodeling Process 
Sina L. Moainie, T. Sloane Guy, IV, Joseph H. Gorman, III, Martin St. John-Sutton, Robed 
C. Gorman, University of Pennsylvania, Philadelphia, Pennsylvania. 
iNTRODUCTION: Post-infarction left ventricolar (LV) remodeling causes heart failure as 
a result of LV aneurysm (LVA) formation, ischemic mitral regurgitation (IMR) or ischemic 
cardiomyopathy (ICM), We hypothesized that early post-infarction changes in LV shape 
predict the ultimate outcome of the remodeling process, METHODS: Three groups of 5 
sheep underwent infarction (MI) of 23% of the left ventricle. Infarction in Group ~ led to 
LVA, in Group II it led to progressive IMR, and in Group III it led to ICM without IMR or 
LVA. All animals underwent echocardiography at baseline and 1 hr, 2, 5 and 8 weeks 
after MI to assess remodeling and LV shape changes. LV shape was assessed by the 
ratio of the LV internal diameter at end-systole to the left ventricular long axis length at 
end-systole (sphericity index). RESULTS: Group I (LVA) had immediate decline in ven- 
tricular sphericity after MI that persisted throughout he remodeling. Group II (IMR) had 
an increase in LV sphericity immediately that progressed over eight weeks. Group III 
(ICM) animals did not experience early changes in left ventdcular sphericity but had a 
progressive increase in sphericity over the eight-week study period. CONCLUSION: 
After MI, early changes in LV sphericity predict the final result of LV remodeling. An 
immediate increase in LV sphericity is correlated with the development of IMR while a 
delayed increase is seen with ICM. An early decrease is associated with LV aneurysm. 
Left Ventrlcular Sphericity Index 
"rimepoint Group I (LVA) Group II (IMR) Group III (ICM) 
Baseline 0.49(±0.04) 0.48(±0.03) 0.47(±0.08) 
1 Hour Post-Infarction 0.44(±0.06)* 0.52(±0.04) * 0.47(±0.09) 
2 Weeks Post-Infarction 0.44(±0.04) 0.54(±0.06) 0.48(±0.09) 
5 Weeks Post-Infarction 0,40(±0.08) 0,54(±0.06) 0.49(±0.09) 
8 Weeks Post-Infarction 0.41(±0.07) ^ 0.56(±0.08) ^ 0.54(±0.06) ^ 
*p<0.05 1 hour compared to baseline ^p<0.05 8 weeks compared to baseline 
5:15 p.m. 
838FO-6 Endothelln Antagonism With Bosentan Improves 
Myocardial Mechanics and Ventricular Remodeling in 
Rats With Chronic Heart Failure 
~noeboro Schafhalter-Zooooth. John R. Teerlink, San Francisco VA Medical Center, San 
Francisco, California, UCSF, San Francisco, California. 
Background: The effect of ET antagonists on ventricular emodeling in CHF remains con- 
troversial and there has been limited investigation of the functional effects of ET blockade 
in CHF. We hypothesized that chronic therapy with bosentan would not only result in 
attenuation of progressive ventricular dilation, but would also result in functional improve- 
ments in myocardial mechanics. 
Methods: Adult male Sprague-Dawley rats (270-300g) underwent coronary artery ligation 
(CAL) and rats with ejection fraction <40% on conscious echocardiography at day 5-7 
after surgery were assigned to the CHF group. One week after surgery the animals were 
randomized to Placebo(P) or Bosentan (B;100 mg/kg/d) as a food additive. After 8 weeks 
of treatment, the animals underwent conscious echocardiography and in vivo hemody- 
namics and assessment of cardiac mechanics with a conductance catheter. The heads 
were excised and diastolic pressure-volume curves were obtained (n>9 in all groups). 
Results: Baseline data (EF, body weight) showed no differences between the treatment 
groups. There were no differences in body weight at 8 weeks, but echo EF was higher in 
the bosentan group (B, 26.4±2.3%, vs. P, 19.4±1.7%; p=0.028) and LVEDP was lower 
(B, 20.2±3.4 mmHg, vs. P, 29.5±2.5; p=0.05). Conductance catheter measurements 
demonstrated that bosentan treated rats had increased stroke volume (p=0.02), cardiac 
output (p=0.0:~), and increased maximal power (B, 93.5±17.5 mW, vs. P, 36.6±5.3; 
p=0.006; preload adjusted, p=0.01 ). Vena caval occlusions demonstrated a trend toward 
increased Ees (p=0.12) and ex vivo passive pressure-volume curves demonstrated 
marked reductions in ventricular volumes (LVEDVI @20mmHg: B, 2.17-~-0.17 ml/kg, vs. P, 
2.78±0.13; p=0.01) in the bosentan treated group, but no differences in stiffness con- 
stants over the 10-30 mmHg range. 
Conclusion: These data demonstrate that chronic ET blockade with bosentan results not 
only in significant attenuation of ventricular dilation, but also markedly improves ventricu- 
lar function. Whether this improvement ranslates into symptomatic benefit in patients is 
being studied in current clinical trials. 
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839-1 Vasopressin Receptor Blockade With Tolvaptan in 
Chronic Heart Failure: Differential Effects in 
Normonatremic and Hyponatremic Patients 
Mihai Gheorehiade, Marvin A. Konstam, James E. Udelson, John Ouyang, Cesare 
Odandi, Northwestern University School of Medicine, Chicago,///inois. 
Background: We have reported that chronic vasopressin V2 receptor blockade with 
tolvaptan (TLV) in pts with congestive heart failure (HF) reduces body weight and edema, 
and increases serum Na+. However, the effects of tolvaptan in HF patients with 
hyponafremia re not known. 
Methods: After a 3-day run-in period, 250 pts with HF and signs of congestion were ran- 
domized to placebo (n=62), TLV 30 mg (n=64), 45 mg (n=62) or 60 mg (n=62) qd for 25 
days. Pts were on standard therapy, not fluid restricted, and maintained on stable furo- 
semide (20-240 rng/day) throughout he study. 
Results: At baseline, hyponatremia (serum Na+ _<136 mEq/L) was seen in 34, 23, 23, and 
32 % of the placebo, TLV 30, 45, and 60 mg pts respectively. A significant and dose- 
dependent increase in urine volume was observed with TLV at day 1 in both nor- 
monatremic and hyponatremic pts. Changes in body weight (kg) and serum Na+ (mEqJL) 
at day 1 and 25 are shown in the table. No changes in serum K+ or other laboratory val. 
ues, and BP were observed. In patients with HF and signs of congestion, TLV therapy 
reduced body weight and edema to a similar degree irrespective of serum sodium at 
baseline. Although serum Na+ increased at day 1 in both groups, if returned to baseline 
by day 25 in normonatremic pts, while remained normalized in hyponatremic pts. 
Conclusions: In addition to reducing body weight and lessening edema, "{'LV therapy nor- 
malizes serum sodium in pts with HF and hyponatremia. 
Day PLC TLV 30mg TLV 45mg TLV 60mg 
Body Weight Hypo 1 +0.3±1.0 -0.2±0.7 -1.2±1.5" -0.5±1.2" 
25 +0.4±1.8 -0.4±1,7 -1.3±3.3* -0.7±1.5 
Normo 1 +0.3±1.7 -1.0±1.0" -0.9±2.0" -0.9±0.9* 
25 +0.7±2.2 -1.0±2.3* -1.0±2.1 -0.4±2.0* 
Serum Sodium Hypo 1 +1.2±1.6 +3,6±2.1" +3.3±2.4* +5.2±2.1" 
25 +1.0±2,8 +2.1±4,2 +1.5±2.3 +4.3±2.4* 
Normo 1 -1.8±7.4 +2.3±2.4* +2.9±2.4* +2.6±2.5* 
25 -0.6±2.8 +0.2±2.5 -0,5±3.0 -0.4±2.6 
4:15 p.m. 
839*2 Cardiac Resynchronization Therapy Reduces Morbidity 
in Patients With Moderate to Severe Systolic Heart 
Failure and Intraventricular Conduction Delays 
William T. Abraham. Westby Fisher, Andrew Smith, David DeLurgio, Evan Loh, Angel 
Leon, Dusan Kocovic, Alfredo Clavell, David Hayes, University of Kentucky, Lexington, 
Kentucky, Crawford Long./Emoty University Hospital, University of Pennsylvania, Mayo 
Clinic. 
Background: Cardiac resynchronization therapy (CRT) has been demonstrated to 
improve exercise capacity, quality of life and cardiac function in moderate to severe heart 
failure patients with systolic dysfunction and a wide QRS. The impact of CRT on survival 
and hospitalization for heart failure has not been determined. Methods: The Multicenter 
InSync Clinical Evaluation included secondary objectives to assess survival and hospital- 
ization. Inclusion criteria were: NYHA Class III or IV HI=, LVEF 3 35%, LVEDD 3 55 mm, 
stable and optimal medical regimen, and a QRS duration 3130 msec, without pacing indi- 
cations. All patients were implanted with a CRT system. Patients were randomly 
assigned to either CRT or no CR (Contro}) for 6 months. Using a time to event analysis 
our objective for this substudy was to assess the impact of CRT on survival and hospital- 
ization in a 6 month period. Results: A total of 225 patients were assigned to the Control 
group, and 228 were assigned to CRT. Freedom from an event (95% CI) at 6 months for 
Control is 81.0% (75.1%, 85.6%), and for CRT is 87.3% (82.0%, 91.1%) with a relative 
risk of 0.615 (0.382, 0.990), P=0.043. Conclusion: CRT improves the freedom from major 
morbid events for select heart failure patients. 
4:30 p.m. 
839-3 Efficacy and Safety of Carvedilol In Patients With 
Severe Chronic Heart Failure and Low Systolic Blood 
Pressure: Results of the COPERNICUS Study 
Jean L. Rouleau. Michael B, Fowler, Henry Krum, Hugo A. Katus, Andrew J. Coats, 
Michal Tenders, Paul Mohacsi, Ildika Amann-Zalan, Terry L Holcslaw, Ellen B. Roecker, 
Milton Packer, for the COPERNICUS Study Group, Mt. Sinai Hospital, Toronto, Canada. 
Background. Since survival trials with metoprolol and bisoprolol excluded patients with a 
systolic blood pressure (SBP) < 100mm Hg, many physicians are reluctant to use ~- 
blockers in such patients, especially those with a vasodilatory effect. 
Methods. We evaluated the effects of carvedilol (CRV) vs placebo (PBO) in 2289 patients 
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with severe heart failure (HF) in the COPERNICUS study, of whom 132 had a SBP of 85- 
95 mm Hg and 264 had a SBP of 96-105 mm Hg at the time of randomization. Following 
initiation of treatment, SBP increased (CRV>PBO) in the patients with low SBP and fell 
transiently (CRV>PBO) in the patients with higher SBP. Results (see table): 
All-Cause Mortality Death or HF Hospitalization 
1-year PBO Hazard ratio 1-year PBO Hazard ratio 
rate (CRV:PBO) rate (CRV:PBO) 
85-95 mm Hg 34% 0.77 61% 0.74 
96-105 mm Hg 25% 0.61 43% 0.75 
106-115 mm Hg 18% 0,65 37% 0.78 
116-125 mm Hg 17% 0.61 40% 0.54 
> 125 mm Hg 15% 0.60 32% 0.68 
Patients with low baseline SBP were at extremely high risk of a major clinical event, the 
magnitude of risk decreasing with increasing SBP. However, CRV decreased the risk of 
death and of death or HF hospitalization in all SBP subgroups, the magnitude of benefit 
being independent of SBP (interaction P=0.64 and P=0.80 for mortality and for death or 
HF hospitalization, respectively). The rate of permanent withdrawal decreased with 
increasing baseline SBP (P=0.0001), similarly for PBO and CRV (interaction P=0.25). 
Hypotension was reported as an adverse effect more with CRV than PBO overall; this dif- 
ference was not accentuated in the low SBP subgroups. 
Conclusions. These results provide the first evidence that CRV is effective and wen toler- 
atsd in patients with severe HF and a low SBP. 
4:45 p.m. 
839-4 The Carvedl lo l  Hibernation Reversible Ischemia Trial: 
Marker of Success (CHRISTMAS) 
John G. Cleland. D. J. Pennell, S. G. Ray, A. J. Coats, A. Lahiri, P. W, Macfarlane, J. 
Dalle Mule, Z. Vered, G. Murray, for the CHRISTMAS Investigators, Castle Hill Hospital, 
Kingston Upon Hill, United Kingdom. 
Background: Improved left ventitcular ejection fraction (LVEF) in response to beta-block- 
ers is a consistent finding in dilated cardiomyopathy while it is less consistent in 
ischaemic heart disease (IHD). This heterogeneous response could be explained by the 
volume of hibernating mycoardium or of scarred myocardium. 
Methods: Patients with chronic heart failure (HF) of ischaemic etiology and left ventricular 
systolic dysfunction (wall motion (WM) index _< 1.3 by echcoardiography, corresponding 
to a LVEF -< 39%) were enrolled in this international double-blind randomised trial. The 
primary objective was to determine whether the presence of hibernating myocardium 
predicted the magnitude of improvement in LVEF in response to carvedilol or placebo. 
Myocardial status (hibernating or non-hibernating) was assessed by correlating the 
echocardiographic WM findings to the results of myocardial perfusion imaging (MPI). 
Hibernation was defined as a regional mismatch between impaired WM with preserved 
myocardial perfusion by MPI. Baseline LVEF was assessed by radionuclide ventdculog- 
raphy (RNVG). Echocardiographic and nuclear studies were blindly assessed by core 
laboratories. Hibernators and non-hibernators were stratified into two treatment groups of 
similar size, randomised to carvediloJ or placebo, and titrated up to 25 mg bid. The total 
duration of the trial was about 6 months. 
Results: 305 patients were included in the analysis: 90% males (mean age 62 years), 
73% angina-free during daily activity, 60% in NYHA class II, 29% in class IlL Mean base- 
line LVEF was 29 ± 11% (SD). 181 (59%) were classified as hibernators. LVEF was 
unchanged after 6 months in patients on placebo regardless of myocardial status. Both 
the hibernating and non-hibemating groups showed significant LVEF improvement with 
carvedilol. Within the carvedilol group, patients with lower LVEF and larger volumes of 
hibemating myocardium had a greater LVEF response. 
Conclusion: These data suggest that some of the effect of carvedilol on LVEF may be 
mediated through improvement of hibernating myocardium. Medical therapy may be an 
important adjunct or alternative to revascularisation for patients with hibernating myocar- 
dium. 
5:00 p,m. 
839-5 Ef fects  of  Valsartan on Morbidity and Morta l i ty  in Heart 
Failure Patients Not Receiving ACE Inhibitors 
~,ldo P. Maooioni, Inder Anand, Sidney O. Gottlieb, Roberto Latini, Gianni Tognoni, Jay 
N. Cohn, on the behalf of VaI-HeFT Investigators, GISSI Group, Milano, Italy, University 
of Minnesota Hospital and Clinic, Minneapolis, Minnesota. 
Background: ACE-inhibitors (ACE-i) reduce mortality and morbidity in lots with chronic 
heart failure (CHF). Nonetheless, nearly 20% of potentially eligible pts may not be pre- 
scribed on ACE-i. 
Aim: To evaluate the effects of the angiotensin II receptor blocker (ARB) valsartan (V) in 
the pts randomized in the VaI-HeFT trial not receiving ACE-inhibitors. 
Methods and Results: VaI-HeFT was an international, randomized, double-blind trial test- 
ing V vs placebo (P) when added to the prescribed treatment of pts with CHF. The two 
primary end points were all-cause mortality and morbidity defined as all-cause deeth. 
resuscitated sudden death, hospitaJization for CHF, or administration of iv inotropes or 
vasodilatore for >= 4h without hospitalization. Of the 5010 pts enrolled in the tdal, 366 
(9.3%) were not treated with ACE-i at baseline, but 39% were on betablcokers. Pts 
already on treatment with an ARB were excluded. Baseline characteristics and concomi- 
tant treatments were comparable in V and P groups not taking ACE-i. Analysis of covari- 
ance was performed to assess the effect of V in this subgroup (Table). 
Conclusion: VaI-HeFT has provided the first placebo-controlled outcome data demon- 
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strating a favorable effect of an ARB on mortality and morbidity in pts with CHF not 
treated with ACE-L The improved left ventricular function and reduction in BNP confirm 
the beneficial effect of V on the progression of CHF. Thus, V can be considered a valid 
alternative to ACE-i in pts who cannot be treated with these recommended drugs. 
V (n=185) P (n=181) p 
All-cause deaths % 17.3 27.1 0.02 
Morbidity % 24.9 42.5 0.0002 
HF Hospitalizations % 27.6 64.6 0.01 
EF % 4:66+/-9.19 1,68+/-8.01 0.0004 
BNP pg/mL -53+/-166 64+/-337 0.0004 
SBP mmHg -8.1+/-1.2 -3.2+/-1.2 0.004 
5:15 p.m. 
839-6 Benef ic ia l  Ef fects  of  Spironolactone Are Independent of  
Baseline Aldostarone Levels in Severe Congestive 
Heart Failure: Results From the RALES Neurohormonal 
Substudy 
Michel F. Rousseau. Annie R. Robert, Jean Marie Ketelslegers, Sylvie A. Ahn, Hubert G. 
Pouleur, University of Louvain, Brussels, Belgium. 
Background : Spironolactone (spiro), an aldosterone (aldo) receptor antagonist, is 
known to improve survival in severe congestive heart failure. 
Methods : To determine if this beneficial effect was also present in patients with low 
baseline aldo plasma levels, aide plasma concentrations (normal value:<0.4nmol/mL) 
were measured in 125 patients (mean EF:25%,NYHA Ill-iV, all treated with ACE-Inibi- 
tots), randomly assigned to spiro (n=61) and placebo (n=64) in the RALES Trial. 
Results : After 24 months of follow-up, 25% of spiro patients had died versus 42% of pta- 
cebo patients (p<0.05). Further, when patients were divided according to baseline aldo 
levels _> to median (0.38nmol/mL), the benefit of spiro was present in all patients regard- 
less of baseline values (see table). Indeed, although overall mortality tended to be higher 
in placebo patients with high baseline values (49%) than those with low baseline values 
(34%), mortality was also higher in the two placebo groups when compared to patients 
treated with spiro (RR for placebo vs spiro : 1,76 [0.85-3.93] and 1.58 [0.63-4.13], [95% 
CI] for high and low baseline values respectively). Given the 95% CI ovedap, these RR 
indicate comparable risk reduction in both spiro groups. 
Conclusions : the beneficial effects of spire on survival are not limited to patients with 
high circulating aldo levels at baseline, suggesting that tissue concentration might play a 
key role in the pathophysiology of congestive heart failure. 
Splronolactone Placebo 
Death Alive Death Alive 
20.38 n=8 n=21 n=17 n=18 
<0.38 n=7 n=25 n=10 n=19 
ORAL CONTRIBUTIONS 
845 Hypertrophic Cardiomyopathy Septal 
Ablation, Athletic Heart, and Doxorubicin 
Toxicity 
Tuesday, March 19, 2002, 8:30 a.m.-lO:O0 a.m. 
Georgia World Congress Center, Room 257W 
8:30 a.m. 
845-1 A lcoho l  Septal  Ab lat ion  for  Hypertrophic Obstructive 
Cardiomyopathy: A New Standard of Care 
Nasser M. Lakkis. Jennifer Franklin, Donna Killip, Sherif S. Nagueh, Robert Roberts, 
William Spencer, III, Baylor College of Medicine, Houston, Texas, MUSC, Charleston, 
South Carolina. 
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy has been introduced 
in the US by our group at Baylor College of Medicine in Nov 1996. The purpose of this 
abstract is to report on the clinical and echcoardiographic long-term outcome of the 219 
patients treated at our institution. The mean age was 51+/-15 years, 133 patients were 
males. The peak CK post ablation rose to 1352+/-915 units. The mean resting gradient 
decreased from 60 +/-36 mm Hg to 19+/-28 at 6 weeks and continued to decrease at one 
year to 10+/- 19 mmHg and 5+/-10 mmHg at 3 years. The provoked gradients decreased 
from 94+/-54 mm Hg to 53+/-65, 42+/-37, and 29+/-36 at 6 weeks, one year and three 
years. Along with these positive results, the septal thickness decreased from 2.07+/-0.5 
cm at baseline to 1.6 +/-0,4, 1.3+/-0.4, and 1.2+/-0.4 cm at 6weeks, one year and three 
years. 
NYHA class symptoms for heart failure decreased from 2.7+/- 0.7 to 0.3+/- at 0.6 at 3 
years. Twenty-four patients had a redo procedure within 4 months of the initial ablation 
for residual gradient, symptoms or both. One patient had a second redo for the same rea- 
sons. Ten patients underwent myomectomies for failure of the ablation procedure to 
relieve their symptoms significantly. Nine out of these ten patients had very small septal 
arteries that supplied only a limited territory of the hypertrophied septum, as evidenced 
by the smaller enzyme peak (443+/-354)in these patients. Nine patients died on follow- 
up, One patinet died after open heart surgery for failed ablation, Two patients had unwit- 
